The Carlyle Group is in exclusive talks to buy clinical research company Pharmaceutical Product Development (PPD) according to Bloomberg.
Individuals involved with the bid confirmed that the bid was taking place and that most were between $33 and $38 a share, or as much as $4.3bn.
PPD’s shares jumped $4.91 (18%) to $31.51 with the NASDAQ Stock Market valuing the company at about $3.6bn.
The acquisition would be the largest for Carlyle since announcing the $3.9bn purchase of telecommunications-equipment manufacturer CommScope in October.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData